Similarly, bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), demonstrated anti-tumor activity in a phase II trial of recurrent meningiomas (8). The gene discussed is VEGFA; the disease is meningioma.